X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

Content Team by Content Team
27th March 2023
in Drug Development, News

Researchers have identified a molecule that is particularly successful in preventing sickness caused by all known forms of the SARS-CoV-2 virus when put nasally. The molecule could be a valuable tool in preparing for future pandemics because it is designed to block both virus transmission and dissemination.

A compound known as TriSb92, discovered by researchers at the University of Helsinki, has been shown in animal experiments to provide significant protection against coronavirus infection. The chemical recognizes a region in the coronavirus spike protein that is shared by all current forms of the virus and suppresses its action.

The TriSb92 molecule is particularly successful in preventing infection when taken nasally, and cell culture experiments show that it also includes the most recent variations, including XBB, BF7, and BQ.1.1, reveals Postdoctoral Researcher from Professor Kalle Saksela’s research group, Anna R. Makela.

Animal experiments have also shown that, unlike face masks, the molecule can prevent infection even after a few hours of treatment when sprayed into the nose.

According to the researchers, the molecule can be used as a nasal spray because it can remain fully active at room temperature for at least 18 months. The research was released in the journal Nature Communications.

While the worst of the coronavirus has passed, nasally delivered protection can be of critical assistance in avoiding the virus’s spread in the future. According to Makela, the most recent versions efficiently bypass the immunological protection afforded by both vaccines and the COVID-19 disease, and current vaccines are ineffective in preventing transmission.

Furthermore, the nasal spray can protect those from dangerous diseases who do not obtain enough immunity from immunisations, such as immunocompromised persons and the elderly. The molecules may also be effective against future animal-borne close relatives of SARS-CoV-2, which are likely to create new coronavirus pandemics, according to the researchers.

Because the area in the coronavirus’s spike protein impacted by the TriSb92 molecule has remained largely unaltered in all viral variants that have surfaced thus far, Makela believes it will be effective against future SARS-CoV-2 variants as well. She adds that the simply and cheaply generated TriSb92 could be a critical first line of defence in containing such a new pandemic, awaiting the development, production, and distribution of vaccines.

The sherpa body technology utilised by the researchers is also applicable to the protection of many other viral infections, particularly influenza and other respiratory viruses, as per researchers.

According to Makela, the entire strategy is based on a technical solution created in Finland that was not originally intended for the creation of an antiviral medication. It opens the door to many additional innovative projects based on the exact detection of sick cells or pathogens in patients. The molecule must then be examined in clinical studies before it may be made economically available.

Previous Post

Mid-Point Regulatory Science Strategy Study Published By EMA

Related Posts

FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
U.S. FDA Approves DARZALEX Split-Dosing Regimen
Drug Development

EMA Keeping A Close Watch On Critical Medicine Shortages

22nd March 2023

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In